Cover Image
市場調查報告書

成人用疫苗的全球市場:企業分析、預測 (∼2021年)

Global - Adult Vaccines Market, Company Analysis and Forecast to 2021

出版商 iGate Research Pvt Ltd 商品編碼 365301
出版日期 內容資訊 英文 239 Pages
訂單完成後即時交付
價格
Back to Top
成人用疫苗的全球市場:企業分析、預測 (∼2021年) Global - Adult Vaccines Market, Company Analysis and Forecast to 2021
出版日期: 2016年08月03日 內容資訊: 英文 239 Pages
簡介

全球成人用疫苗的市場在預測期間內,預計約以6%的年複合成長率 (CAGR) 成長。成人用疫苗的接受度的高漲和公共衛生部門著重流感預防,新疫苗的引進等促進該市場的成長。

本報告提供全球成人用疫苗的市場調查,成人用疫苗的市場規模的變化與預測,疾病區分、地區、各企業的明細及佔有率,主要企業的銷售額預測,配合措施,市場成長的推進因素及課題分析等彙整資料。

第1章 摘要整理

第2章 全球成人用疫苗:分析、預測

  • 全球成人用疫苗的市場、預測
  • 全球成人用疫苗:成人接種者數、預測

第3章 全球成人用疫苗市場佔有率:分析、預測

  • 各疾病的成人接種者數的佔有率、預測
  • 各疾病的市場佔有率、預測
  • 各企業的市場佔有率、預測
  • 主要企業的各疾病銷售額佔有率、預測
    • GlaxoSmithKline (GSK)
    • Sanofi Pasteur
    • Merck
    • Novartis
  • 各疾病的企業佔有率、預測
    • 流感
    • 子宮頸癌/HPV
    • 肝炎
    • 肺炎球菌
    • 腦膜炎
    • DTP (百日咳、白喉、破傷風)
  • 各地區佔有率、預測

第4章 全球成人用疫苗市場:各疾病分析

  • 流感
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 子宮頸癌/ HPV
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 帶狀皰疹
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 肺炎球菌
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 腦膜炎
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 麻疹、腮腺炎、德國麻疹、帶狀皰疹 (MMRV)
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 肝炎
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 百日咳、白喉、破傷風 (DTP)
    • 成人用疫苗市場、預測
    • 成人接種者數、預測
    • 疫苗給藥數、預測
  • 旅遊用、其他疫苗

第5章 全球成人用疫苗市場:企業分析、策略性聯盟

  • GlaxoSmithKline
  • Sanofi Pasteur
  • Merck
  • Novartis
  • Pfizer
  • bioCSL (Now Seqirus)
  • Protein Sciences
  • 其他
    • 成人用疫苗的銷售額、預測
    • 策略性聯盟

第6章 全球成人用疫苗:各疾病的企業銷售額、預測

  • GlaxoSmithKline (GSK):銷售額、預測
    • 流感
    • 子宮頸癌/HPV
    • 肝炎
    • DTP
    • 腦膜炎
  • Sanofi Pasteur:銷售額、預測
    • 流感
    • DTP
    • 腦膜炎
  • Merck:銷售額、預測
    • 子宮頸癌/HPV
    • 帶狀皰疹
    • 肺炎球菌
    • MMRV
    • 肝炎
  • Novartis:銷售額、預測
    • 流感
    • 腦膜炎
  • Pfizer:銷售額、預測
    • 肺炎球菌
  • bioCSL:銷售額、預測
    • 流感
  • Protein Sciences:銷售額、預測
    • 流感

第7章 全球成人用疫苗市場:地區分佈、預測

  • 美國:市場、預測
  • 北美、加勒比海各國:市場、預測
  • 南美:市場、預測
  • 歐洲:市場、預測
  • 日本:市場、預測
  • 印度:市場、預測
  • 中國:市場、預測
  • 其他:市場、預測

第8章 主要疫苗相關的收購

第9章 成人用疫苗市場:成長推進因素

第10章 成人用疫苗市場:課題

圖表

目錄

The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 6% over the next five years. Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continue to be one of the growing segment for pharmaceutical companies. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines capture maximum share of the total adult vaccines market. It is the most popular and accepted vaccination amongst adults. The hepatitis vaccines account for second highest share of the total adult vaccines market in 2015. The HPV/cervical cancer vaccines and pneumococcal vaccines captures the third and fourth highest share of the adult vaccines market respectively in 2015. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.

Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquired Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second position in the adult vaccines market landscape. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer stands at the fourth spot in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza vaccines market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in the influenza vaccines landscape, while in the cervical cancer vaccines market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis, the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japan's adult vaccines market share is expected to remain flat during the forecasting period, while China's adult vaccines market is likely to show continuous growth. South America and India are competing closely with each other to grab maximum share of the adult vaccines market pie.

This is the 2nd edition report on Adult Vaccines Market by iGATE RESEARCH. The report titled "Global - Adult Vaccines Market, Company Analysis and Forecast to 2021" is a 239 Page report with 141 Figures and 12 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

The 9 Diseases covered in the report are analyzed from four viewpoints:

  • 1. Adult Vaccines Market (2007 - 2021)
  • 2. Number of Adults Vaccinated (2007 - 2021)
  • 3. Number of Doses (2007 - 2021)
  • 4. Company Sales Share (2010 - 2021)

The 7 Companies covered in the report are analyzed from two viewpoints:

  • 1. Disease Wise - Adult Vaccines Sales (2007 - 2021)
  • 2. Strategic Alliances

The 8 Region covered in the report are analyzed from one viewpoint:

  • 1. Adult Vaccines Market (2011 - 2021)

Global Adult Vaccines Market, Number of Adults Vaccinated and Doses - Disease Wise Analysis to 2021 (9 Disease Analysed)

  • 1. Influenza
  • 2. Cervical Cancer
  • 3. Zoster Shingles
  • 4. Pneumococcal
  • 5. Meningococcal
  • 6. MMRV
  • 7. Hepatitis
  • 8. DTP
  • 9. Travel and Miscellaneous

Global Adult Vaccines Market - Company Analysis to 2021 (7 Companies Analysed)

  • 1. GlaxoSmithKline
  • 2. Sanofi Pasteur
  • 3. Merck
  • 4. Novartis
  • 5. Pfizer
  • 6. bioCSL (Seqirus)
  • 7. Protein Sciences
  • 8. Other Companies

Global Adult Vaccines Market - Regional Distribution to 2021 (8 Region Analysed)

  • 1. United States
  • 2. North America/Caribbean
  • 3. South America
  • 4. Europe
  • 5. Japan
  • 6. India
  • 7. China
  • 8. Rest of the World

Data Sources

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government and NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries and Local Councils and a large number of Paid Databases.

Table of Contents

1. Executive Summary

2. Global - Adult Vaccines Analysis and Forecast (2007 - 2021)

  • 2.1 Global Adult Vaccines Market and Forecast
  • 2.2 Global Adult Vaccines - Number of Adults Vaccinated and Forecast

3. Global Adult Vaccine Market Share Analysis and Forecast (2010 - 2021)

  • 3.1 Global Adult Vaccines - Disease Wise Adults Vaccinated Share and Forecast
  • 3.2 Global Adult Vaccines - Disease Wise Market Share and Forecast
  • 3.3 Global Adult Vaccines - Company Wise Market Share and Forecast
  • 3.4 Companies Adult Vaccines - Disease Wise Sales Share and Forecast
    • 3.4.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share and Forecast
    • 3.4.2 Sanofi Pasteur - Adult Vaccines Sales Share and Forecast
    • 3.4.3 Merck - Adult Vaccines Sales Share and Forecast
    • 3.4.4 Novartis - Adult Vaccines Sales Share and Forecast
  • 3.5 Adult Vaccine Disease Wise Market - Company Share and Forecast
    • 3.5.1 Influenza Adult Vaccines - Company Market Share and Forecast
    • 3.5.2 Cervical Cancer/HPV Adult Vaccines - Company Market Share and Forecast
    • 3.5.3 Hepatitis Adult Vaccines - Company Market Share and Forecast
    • 3.5.4 Pneumococcal Adult Vaccines - Company Market Share and Forecast
    • 3.5.5 Meningococcal Adult Vaccines - Company Market Share and Forecast
    • 3.5.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines - Company Market Share and Forecast
  • 3.6 Global Adult Vaccines Market - Region Wise Share and Forecast

4. Global Adult Vaccine Market - Disease Wise Analysis

  • 4.1 Influenza - Adult Vaccine Analysis and Forecast (2007 - 2021)
    • 4.1.1 Influenza - Adult Vaccine Market and Forecast
    • 4.1.2 Influenza - Number of Adults Vaccinated and Forecast
    • 4.1.3 Influenza - Number of Vaccines Doses and Forecast
  • 4.2 Cervical Cancer/ HPV - Adult Vaccine Analysis and Forecast (2007 - 2021)
    • 4.2.1 Cervical Cancer/ HPV - Adult Vaccine Market and Forecast
    • 4.2.2 Cervical Cancer/ HPV - Number of Adults Vaccinated and Forecast
    • 4.2.3 Cervical Cancer/ HPV - Number of Vaccines Doses and Forecast
  • 4.3 Zoster Shingles - Adult Vaccine Analysis and Forecast (2007 - 2021)
    • 4.3.1 Zoster Shingles - Adult Vaccine Market and Forecast
    • 4.3.2 Zoster Shingles - Number of Adults Vaccinated and Forecast
    • 4.3.3 Zoster Shingles - Number of Vaccines Doses and Forecast
  • 4.4 Pneumococcal - Adult Vaccine Analysis and Forecast (2010 - 2021)
    • 4.4.1 Pneumococcal - Adult Vaccine Market and Forecast
    • 4.4.2 Pneumococcal - Number of Adults Vaccinated and Forecast
    • 4.4.3 Pneumococcal - Number of Vaccines Doses and Forecast
  • 4.5 Meningococcal - Adult Vaccine Analysis and Forecast (2010 - 2021)
    • 4.5.1 Meningococcal - Adult Vaccine Market and Forecast
    • 4.5.2 Meningococcal - Number of Adults Vaccinated and Forecast
    • 4.5.3 Meningococcal - Number of Vaccines Doses and Forecast
  • 4.6 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Analysis and Forecast (2010 - 2021)
    • 4.6.1 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Market and Forecast
    • 4.6.2 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Adults Vaccinated and Forecast
    • 4.6.3 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Vaccines Doses and Forecast
  • 4.7 Hepatitis - Adult Vaccine Analysis and Forecast (2007 - 2021)
    • 4.7.1 Hepatitis - Adult Vaccine Market and Forecast
    • 4.7.2 Hepatitis - Number of Adults Vaccinated and Forecast
    • 4.7.3 Hepatitis - Number of Vaccines Doses and Forecast
  • 4.8 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Analysis and Forecast (2007 - 2021)
    • 4.8.1 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Market and Forecast
    • 4.8.2 Diphtheria, Tetanus, Pertussis (DTP) - Number of Adults Vaccinated and Forecast
    • 4.8.3 Diphtheria, Tetanus, Pertussis (DTP) - Number of Vaccines Doses and Forecast
  • 4.9 Travel and Miscellaneous - Adult Vaccine Analysis and Forecast (2007 - 2021)

5. Global Adult Vaccine Market - Company Analysis and Strategic Alliances

  • 5.1 GlaxoSmithKline
    • 5.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales and Forecast
    • 5.1.2 Strategic Alliances of GlaxoSmithKline (GSK)
  • 5.2 Sanofi Pasteur
    • 5.2.1 Sanofi Pasteur Vaccines Sales and Forecast
    • 5.2.2 Strategic Alliances of Sanofi Pasteur
  • 5.3 Merck
    • 5.3.1 Merck Vaccines Sales and Forecast
    • 5.3.2 Strategic Alliances of Merck
  • 5.4 Novartis
    • 5.4.1 Novartis Vaccines Sales
    • 5.4.2 Strategic Alliances of Novartis
  • 5.5 Pfizer
    • 5.5.1 Pfizer Adult Vaccines Sales and Forecast
    • 5.5.2 Strategic Alliances of Pfizer
  • 5.6 bioCSL (Now Seqirus)
    • 5.6.1 bioCSL Adult Vaccines Sales and Forecast
    • 5.6.2 Strategic Alliances of bioCSL
  • 5.7 Protein Sciences
    • 5.7.1 Protein Sciences Adult Vaccines Sales and Forecast
  • 5.8 Other Companies Sales and Forecast

6. Global Adult Vaccine - Disease Wise Company Sales and Forecast (2007 - 2021)

  • 6.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales and Forecast
    • 6.1.1 GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales and Forecast
    • 6.1.2 GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
    • 6.1.3 GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales and Forecast
    • 6.1.4 GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales and Forecast
    • 6.1.5 GlaxoSmithKline (GSK) - Meningococcal Adult Vaccines Sales and Forecast
  • 6.2 Sanofi Pasteur - Adult Vaccines Sales and Forecast
    • 6.2.1 Sanofi Pasteur - Influenza Adult Vaccines Sales and Forecast
    • 6.2.2 Sanofi Pasteur - DTP Adult Vaccines Sales and Forecast
    • 6.2.3 Sanofi Pasteur - Meningococcal Adult Vaccines Sales and Forecast
  • 6.3 Merck - Adult Vaccines Sales and Forecast
    • 6.3.1 Merck - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
    • 6.3.2 Merck - Zoster Shingles Adult Vaccines Sales and Forecast
    • 6.3.3 Merck - Pneumococcal Adult Vaccines Sales and Forecast
    • 6.3.4 Merck - MMRV Adult Vaccines Sales and Forecast
    • 6.3.5 Merck - Hepatitis Adult Vaccines Sales and Forecast
  • 6.4 Novartis - Adult Vaccines Sales and Forecast
    • 6.4.1 Novartis - Influenza Adult Vaccines Sales and Forecast
    • 6.4.2 Novartis - Meningococcal Adult Vaccines Sales and Forecast
  • 6.5 Pfizer - Adult Vaccines Sales and Forecast
    • 6.5.1 Pfizer - Pneumococcal Adult Vaccines Sales and Forecast
  • 6.6 bioCSL - Adult Vaccines Sales and Forecast
    • 6.6.1 bioCSL - Influenza Adult Vaccines Sales and Forecast
  • 6.7 Protein Sciences - Adult Vaccines Sales and Forecast
    • 6.7.1 Protein Sciences - Influenza Adult Vaccines Sales and Forecast

7. Global Adult Vaccine Market - Regional Distribution (2011 - 2021)

  • 7.1 United States - Adult Vaccine Market and Forecast
  • 7.2 North America/Caribbean - Adult Vaccine Market and Forecast
  • 7.3 South America - Adult Vaccine Market and Forecast
  • 7.4 Europe - Adult Vaccine Market and Forecast
  • 7.5 Japan - Adult Vaccine Market and Forecast
  • 7.6 India - Adult Vaccine Market and Forecast
  • 7.7 China - Adult Vaccine Market and Forecast
  • 7.8 Rest of the World (ROW) - Adult Vaccine Market and Forecast

8. Major Vaccine Related Acquisitions (2005-2015)

9. Adult Vaccines Market - Driving Factors

  • 9.1 GAVI Model Fuelling Vaccine Manufacturers
    • 9.1.1 The Partnership Model
    • 9.1.2 The Business Model
  • 9.2 Global Immunization Vision and Strategy (GIVS)
  • 9.3 Growing Vaccine Availability in United States
  • 9.4 The Vaccine Injury Compensation Program
  • 9.5 The Vaccine Safety Data link Project
  • 9.6 Transformation of Vaccine Technologies
  • 9.7 Global Vaccine Action Plan by WHO (2011 - 2020)
  • 9.8 Continuous Focus on Effective Communication Strategies

10. Adult Vaccines Market - Challenges

  • 10.1 Hurdles to Optimal use of Licensed Vaccines
    • 10.1.1 Technical Obstacles
    • 10.1.2 Economic obstacles
    • 10.1.3 Cultural Obstacles
  • 10.2 Shortening the Timeline for Vaccine Development
  • 10.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
    • 10.3.1 Legal Obstacles
    • 10.3.2 General Technical Barriers
    • 10.3.3 Economic Barriers
    • 10.3.4 Regulatory Barriers
  • 10.4 Refusal/Resistance to Vaccination
  • 10.5 Vaccine Adverse Event Reporting System
  • 10.6 Vaccine Shortages and Delays
  • 10.7 Obstacles in Vaccine Research and Development
  • 10.8 Barriers to New Entrants in the Vaccines Market

List of Figures:

  • Figure 2-1: Global - Adult Vaccines Market (Million US$), 2007 - 2015
  • Figure 2-2: Global - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 2-3: Global - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 2-4: Global - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 3-1: GlaxoSmithKline (GSK) - Adult Vaccines Sales Share (Percent), 2009 - 2015
  • Figure 3-2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
  • Figure 3-3: Sanofi Pasteur - Adult Vaccines Sales Share (Percent), 2010 - 2015
  • Figure 3-4: Sanofi Pasteur - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
  • Figure 3-5: Merck - Adult Vaccines Sales Share (Percent), 2010 - 2015Error! Bookmark not defined.
  • Figure 3-6: Merck - Forecast for Adult Vaccines Sales Share (Percent), 2016 - 2021
  • Figure 3-7: Novartis - Adult Vaccines Sales Share (Percent), 2010 - 2014
  • Figure 3-8: Cervical Cancer/HPV Adult Vaccines - Company Market Share (Percent), 2007 - 2015
  • Figure 3-9: Cervical Cancer/HPV Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
  • Figure 3-10: Hepatitis Adult Vaccines - Company Market Share (Percent), 2008 - 2015
  • Figure 3-11: Hepatitis Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
  • Figure 3-12: Pneumococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2015
  • Figure 3-13: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
  • Figure 3-14: Meningococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-15: Pneumococcal Adult Vaccines - Company Market Share and Forecast (Percent), 2015 - 2021
  • Figure 3-16: DTP Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-17: DTP Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
  • Figure 3-18: Region Wise - Adult Vaccines Market Share (Percent), 2011 - 2015
  • Figure 3-19: Region Wise - Forecast for Adult Vaccines Market Share (Percent), 2016 - 2021
  • Figure 4-1: Influenza - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-2: Influenza - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-3: Influenza - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 4-4: Influenza - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-5: Influenza - Number of Vaccines Doses (Million), 2007 - 2015
  • Figure 4-6: Influenza - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-7: Cervical Cancer/ HPV - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-8: Cervical Cancer/ HPV - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-9: Cervical Cancer/ HPV - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 4-10: Cervical Cancer/ HPV - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-11: Cervical Cancer/ HPV - Number of Vaccines Doses (Million), 2007 - 2015
  • Figure 4-12: Cervical Cancer/ HPV - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-13: Zoster Shingles - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-14: Zoster Shingles - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-15: Zoster Shingles - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 4-16: Zoster Shingles - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-17: Zoster Shingles - Number of Vaccines Doses (Million), 2007 - 2015
  • Figure 4-18: Zoster Shingles - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-19: Pneumococcal - Adult Vaccine Market (Million US$), 2010 - 2015
  • Figure 4-20: Pneumococcal - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-21: Pneumococcal - Number of Adults Vaccinated (Million), 2010 - 2015
  • Figure 4-22: Pneumococcal - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-23: Pneumococcal - Number of Vaccines Doses (Million), 2010 - 2015
  • Figure 4-24: Pneumococcal - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-25: Meningococcal - Adult Vaccine Market (Million US$), 2010 - 2015
  • Figure 4-26: Meningococcal - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-27: Meningococcal - Number of Adults Vaccinated (Million), 2010 - 2015
  • Figure 4-28: Meningococcal - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-29: Meningococcal - Number of Vaccines Doses (Million), 2010 - 2015
  • Figure 4-30: Meningococcal - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-31: MMRV - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-32: MMRV - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-33: MMRV - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 4-34: MMRV - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-35: MMRV - Number of Vaccines Doses (Million), 2007 - 2015
  • Figure 4-36: MMRV - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-37: Hepatitis - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-39: Hepatitis - Number of Adults Vaccinated (Million), 2007 - 2015
  • Figure 4-40: Hepatitis - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-41: Hepatitis - Number of Vaccines Doses (Million), 2007 - 2015
  • Figure 4-42: Hepatitis - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-43: DTP - Adult Vaccine Market (Million US$), 2010 - 2015
  • Figure 4-44: DTP - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 4-45: DTP - Number of Adults Vaccinated (Million), 2010 - 2015
  • Figure 4-46: DTP - Forecast for Number of Adults Vaccinated (Million), 2016 - 2021
  • Figure 4-47: DTP - Number of Vaccines Doses (Million), 2010 - 2015
  • Figure 4-48: DTP - Forecast for Number of Vaccines Doses (Million), 2016 - 2021
  • Figure 4-49: Travel and Miscellaneous - Adult Vaccine Market (Million US$), 2007 - 2015
  • Figure 4-50: Travel and Miscellaneous - Forecast for Adult Vaccine Market (Million US$), 2016 - 2021
  • Figure 5-1: GlaxoSmithKline (GSK) - Adult Vaccine Sales (Million US$), 2007 - 2015
  • Figure 5-2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-3: Sanofi Pasteur - Adult Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-4: Sanofi Pasteur - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-5: Sanofi Pasteur - Pipeline Vaccines candidates (Phase III), April 2016
  • Figure 5-8: Merck - Adult Vaccine Sales (Million US$), 2007 - 2015
  • Figure 5-9: Merck - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-10: Novartis - Adult Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-11: Pfizer - Adult Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-12: Pfizer - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-13: bioCSL - Adult Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-14: bioCSL - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-15: Protein Sciences - Adult Vaccine Sales (Million US$), 2013 - 2015
  • Figure 5-16: Protein Sciences - Forecast for Adult Vaccine Sales (Million US$), 2016 - 2021
  • Figure 5-17: Other Companies - Adult Vaccine Sales (Million US$), 2010 - 2015
  • Figure 5-18: Other Companies - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 6-1: GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-2: GlaxoSmithKline (GSK) - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-3: GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-4: GlaxoSmithKline (GSK) - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-5: GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-6: GlaxoSmithKline (GSK) - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-7: GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-8: GlaxoSmithKline (GSK) - Forecast for DTP Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-9: GlaxoSmithKline (GSK) - Meningococcal Adult Vaccines Sales and Forecast (Million US$), 2015 - 2021
  • Figure 6-10: Sanofi Pasteur - Influenza Adult Vaccines Sales (Million US$), 2009 - 2015
  • Figure 6-11: Sanofi Pasteur - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-12: Sanofi Pasteur - DTP Adult Vaccines Sales (Million US$), 2010 - 2015
  • Figure 6-13: Sanofi Pasteur - Forecast for DTP Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-14: Sanofi Pasteur - Meningococcal Adult Vaccines Sales (Million US$), 2009 - 2015
  • Figure 6-15: Sanofi Pasteur - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-16: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-17: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-18: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-19: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-20: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-21: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-22: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-23: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-24: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2015
  • Figure 6-25: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-26: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2015
  • Figure 6-27: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-28: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2015
  • Figure 6-29: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-30: bioCSL - Influenza Adult Vaccines Sales (Million US$), 2010 - 2015
  • Figure 6-31: bioCSL - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 6-32: Protein Sciences - Influenza Adult Vaccines Sales (Million US$), 2013 - 2015
  • Figure 6-33: Protein Sciences - Forecast for Influenza Adult Vaccines Sales (Million US$), 2016 - 2021
  • Figure 7-1: United States - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-2: United States - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-5: South America - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-6: South America - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-7: Europe - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-8: Europe - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-9: Japan - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-10: Japan - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-11: India - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-12: India - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-13: China - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-14: China - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 7-15: ROW - Adult Vaccines Market (Million US$), 2011 - 2015
  • Figure 7-16: ROW - Forecast for Adult Vaccines Market (Million US$), 2016 - 2021
  • Figure 9-1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

List of Tables:

  • Table 3-1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2015
  • Table 3-2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2016 - 2021
  • Table 3-3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2015
  • Table 3-4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2016 - 2021
  • Table 3-5: Global Adult Vaccines - Company Wise Market Share (Percent), 2010 - 2015
  • Table 3-6: Global Adult Vaccines - Forecast for Company Wise Market Share (Percent), 2016 - 2021
  • Table 3-7: Influenza Adult Vaccines - Company Market Share (Percent), 2010 - 2015
  • Table 3-8: Influenza Adult Vaccines - Forecast for Company Market Share (Percent), 2016 - 2021
  • Table 8-1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)
  • Table 9-1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
  • Table 9-2: Global Goal-Level Indicators, 2015 & 2020
  • Table 9-3: Improvement Strategies or Requirements - the Joint Commission and the Project's Collaborating Organizations
Back to Top